DelveInsight’s “Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast – 2034” report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment paradigms, and emerging therapies across the 7MM, which include, US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report presents a detailed analysis of pheochromocytomas market trends, therapeutic landscapes, and unmet needs, providing valuable strategic insights for stakeholders in this specialized neuroendocrine tumor market.
The pheochromocytomas and paragangliomas market is poised for significant expansion, with the market size across the 7MM estimated at approximately USD 310 million in 2024. This growth trajectory is primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options targeting specific molecular pathways. The US currently holds the largest pheochromocytoma market share, accounting for approximately USD 190 million in 2024, with promising growth expected in the coming decade due to favorable reimbursement policies and rapid adoption of innovative treatment modalities.
Download the Pheochromocytomas and Paragangliomas Market report to understand which factors are driving the PCPG therapeutic market @ Pheochromocytomas and Paragangliomas Market Trends.
The pheochromocytomas and paragangliomas epidemiological landscape reveals approximately 5K incident cases across the 7MM in 2024, with projections indicating sustained growth throughout the forecast period. Genetic analysis has become increasingly important in pheochromocytomas and paragangliomas management, with nearly 75% of US cases showing germline or somatic mutations in 2024. Among the EU4 and UK markets, which collectively reported approximately 2K incident cases in 2024, Germany accounted for the highest disease burden, while Spain demonstrated the lowest incidence. Japan shows a noteworthy pattern with localized pheochromocytoma cases significantly outnumbering metastatic presentations.
Discover evolving trends in the Pheochromocytomas and Paragangliomas patient pool forecasts @ Pheochromocytomas and Paragangliomas Epidemiology Analysis.
The report also analyses the current and emerging pheochromocytoma and paraganglioma treatment landscape. The current therapeutic landscape varies based on disease staging and functional status. For localized tumors, radical surgical resection remains the cornerstone of treatment, representing the only potentially curative intervention. The metastatic pheochromocytoma treatment paradigm has evolved toward a multidisciplinary approach encompassing debulking surgery, chemotherapy (particularly the cyclophosphamide, vincristine, and dacarbazine regimen), tyrosine kinase inhibitors, immunotherapies, and advanced radionuclide therapies. Radionuclide injection, a targeted treatment option, is also used for pheochromocytoma and paraganglioma treatment, especially in metastatic or inoperable cases.
Key marketed treatments include DEMSER (metyrosine) from Bausch Health (NYSE: BHC) and Ono Pharmaceutical (TYO: 4528). This oral tyrosine hydroxylase inhibitor remains an important option for preoperative preparation and chronic management of malignant pheochromocytoma. In July 2020, the FDA approved Amneal Pharmaceuticals’ generic version of DEMSER oral capsules.
The treatment landscape has faced challenges, including the AZEDRA discontinuation in 2023, due to commercial non-viability. AZEDRA, manufactured by Lantheus Holdings (NASDAQ: LNTH), was approved by the FDA in 2018 based on Study IB12 B.
Despite the challenges associated with drug development for ultra-rare diseases, the pheochromocytomas and paragangliomas pipeline demonstrates significant innovation, with several promising candidates advancing through clinical development.
In January 2025, the FDA accepted for Priority Review a supplemental New Drug Application for Merck’s WELIREG (belzutifan) for treating adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytomas and paragangliomas. Welireg MOA involves blocking HIF-2α, which helps tumors grow in low-oxygen conditions. With a PDUFA date of May 26, 2025, WELIREG is positioned to potentially capture substantial market share upon approval.
Other notable emerging therapies include Chimerix’s ONC201, a first-in-class small molecule imipridone that selectively binds to dopamine receptor D2 and mitochondrial protease ClpP. ONC201 demonstrated a 50% objective response rate in paraganglioma during Phase II studies. Novartis (SWX: NOVN) is advancing LUTATHERA, a radiopharmaceutical that targets somatostatin receptors.
Additionally, in November 2024, Perspective Therapeutics (NYSE: CATX) presented promising initial results from its Phase I/IIa clinical trial of VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium.
Discover recent advancements in the Pheochromocytomas and Paragangliomas treatment landscape @ Pheochromocytomas and Paragangliomas Recent Developments.
The therapeutic landscape is increasingly focusing on targeted approaches based on tumor genetic profiles, with treatments tailored to specific molecular clusters. These include radionuclide therapies with SSTR2 agonists/antagonists, cold SSTR2 analogs, HIF-2α inhibitors, and novel DRD2 and ClpP agonists. This precision medicine approach represents a paradigm shift from traditional symptom management to molecularly targeted interventions that address the underlying pathophysiology of these rare neuroendocrine tumors.
Despite therapeutic advances, significant challenges remain in pheochromocytomas and paragangliomas management, including the heterogeneity of tumor behavior, limited treatment options for metastatic disease, and the need for improved biomarkers to guide therapy selection. The market is expected to witness continued growth driven by increased disease recognition, expanded genetic testing, and the introduction of innovative treatment modalities that address current unmet needs in this specialized oncology segment.
Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. PCPG MARKET OVERVIEW AT A GLANCE
5. KEY EVENTS
6. EPIDEMIOLOGY AND MARKET METHODOLOGY
7. PCPG BACKGROUND AND OVERVIEW
8. PCPG TREATMENT AND MANAGEMENT
9. PCPG EPIDEMIOLOGY AND PATIENT POPULATION
10. PCPG PATIENT JOURNEY
11. PCPG MARKETED DRUGS
12. PCPG DISCONTINUED PRODUCT
13. PCPG EMERGING DRUGS
14. PCPG: SEVEN MAJOR MARKET ANALYSIS
15. PCPG UNMET NEEDS
16. SWOT ANALYSIS
17. KOL VIEWS
18. MARKET ACCESS AND REIMBURSEMENT
19. APPENDIX
20. DELVEINSIGHT CAPABILITIES
21. DISCLAIMER
22. ABOUT DELVEINSIGHT
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
